ArticleDiagnostic pathology2015
CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder.
Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway.Experimental hematology & oncology · 2025Article
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.Cancers · 2022Article
- Article
- Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.Cancer medicine · 2021Article
- Role of the Glycosylphosphatidylinositol-Anchored Protein TEX101 and Its Related Molecules in Spermatogenesis.International journal of molecular sciences · 2020Review
- CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.British journal of cancer · 2020Article
- Gallbladder squamous cell carcinoma: An analysis of 1084 cases from the National Cancer Database.Journal of surgical oncology · 2020Article
- Pure squamous cell carcinoma of the gallbladder locally invading the liver and abdominal cavity: A case report and review of the literature.World journal of clinical cases · 2019Article
- Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer.Journal of pathology and translational medicine · 2019Article
- Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.Oncotarget · 2018Article
- CD109 and squamous cell carcinoma.Journal of translational medicine · 2018Review
- Clinicopathological features and survival of gallbladder squamous cell carcinoma: analysis of 121 cases.International journal of clinical and experimental pathology · 2018Article
- Myxofibrosarcoma primary cultures: molecular and pharmacological profile.Therapeutic advances in medical oncology · 2017Article
- CD109 expression is upregulated in penile squamous cell carcinoma.Oncology letters · 2017Article
- CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX.Oncotarget · 2016Article
- CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.Digestive diseases and sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer is the most common biliary tract malignancy with the worst overall prognosis. CD109 is a co-receptor of TGF-β1 and suppresses TGF-β signaling. In this study, CD109 protein expression in three subtypes of gallbladder cancer was examined by immunohistochemistry on human tissue samples and tissue microarrays. We found that CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7%) and adenosquamous carcinomas (91.7%), but not in adenocarcinomas or normal gallbladder tissues. Thus, CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.